# Nicholas James

Source: https://onco.cc/people/nicholas-james/  
OnCo record `nicholas-james` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Nicholas James is chief investigator of STAMPEDE, the platform trial that reshaped treatment of advanced prostate cancer.

## Summary

Nicholas James is Professor of Prostate and Bladder Cancer Research at The Institute of Cancer Research and a consultant clinical oncologist at The Royal Marsden. His specialisms are prostate cancer, bladder cancer, multi-arm platform trials and radiotherapy. He is chief investigator of STAMPEDE, the multi-arm multi-stage platform trial that established docetaxel and abiraterone in hormone-sensitive metastatic prostate cancer, with the New England Journal of Medicine paper reporting abiraterone for prostate cancer not previously treated with hormone therapy. He has also led trials of chemoradiotherapy in bladder and urothelial cancer. His publications are listed on PubMed.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Professor of Prostate and Bladder Cancer Research, ICR; Consultant Clinical Oncologist, Royal Marsden
- Specialisms: Prostate cancer; Bladder cancer; Multi-arm platform trials; Radiotherapy

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=James%20ND%5BAuthor%5D%20STAMPEDE

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Docetaxel](https://onco.cc/drugs/docetaxel/)
- institutions: [The Institute of Cancer Research](https://onco.cc/institutions/icr-london/), [The Royal Marsden](https://onco.cc/institutions/royal-marsden/), [University College London Hospitals / UCL Cancer Institute](https://onco.cc/institutions/uclh/)
- terms: [Basket, umbrella, and platform trials](https://onco.cc/terms/basket-umbrella-platform/), [Master protocol (platform, basket and umbrella trials)](https://onco.cc/terms/master-protocol/)
- trials: [STAMPEDE](https://onco.cc/trials/stampede/)
- key papers: [STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer](https://onco.cc/key-papers/paper-stampede-abiraterone-nejm-2017/), [STOpCaP: docetaxel or bisphosphonates added to standard of care in hormone-sensitive prostate cancer, a systematic review and meta-analysis](https://onco.cc/key-papers/paper-vale-stopcap-docetaxel-bisphosphonates-lancet-oncol-2016/), [TAX 327: docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer](https://onco.cc/key-papers/paper-tannock-tax-327-docetaxel-prednisone-nejm-2004/)
- people: [Nicholas van As](https://onco.cc/people/nicholas-van-as/)

---
JSON: https://onco.cc/api/v1/entities/nicholas-james.json